SRD5A2 and benign prostatic hyperplasia: SIN therapy downregulated protein expression of SRD5A2 (Figure 2B), AR (Figure 2C), and PSA (Figure 2D) significantly in BPH-1 cells, and SIN treatment decreased the DHT concentration in the supernatants of BPH-1 cells (Figure 2H), which suggested that SIN therapy inhibited the proliferation of BPH-1 cells through the androgen signaling pathway.